Via Microinjection Of Dna Into An Embryo, Egg Cell, Or Embryonic Cell Patents (Class 800/25)
  • Patent number: 9267152
    Abstract: Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3?-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: February 23, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, David Jonathan Heslin, Ka-Man Venus Lai, David M. Valenzuela
  • Patent number: 9040771
    Abstract: Provided herein are mitochondrial-nuclear exchanged cells and animals comprising mitochondrial DNA (mtDNA) from one subject and nuclear DNA (nDNA) from a different subject. Methods for producing a mitochondrial-nuclear exchanged animal and animals made by the methods are provided. Also provided are methods of screening for agents useful for treating a disease or disorder using mitochondrial-nuclear exchanged animals or cells, tissues or organs thereof.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: May 26, 2015
    Assignee: The UAB Research Foundation
    Inventors: Scott Webster Ballinger, Danny R. Welch, Robert Allen Kesterson, Larry W. Johnson
  • Publication number: 20150106964
    Abstract: The methods of producing an organism capable of ingesting and digesting omega-3 rich sources; for producing an organism that desires the consumption of omega-3 rich sources; and for producing an omega-3 enriched hybrid organism are each described. Each method isolates a donor DNA/RNA strand of a donor organism; extracts the donor DNA/RNA strand from the donor organism; and fuses the donor DNA/RNA strand into a receiving DNA/RNA strand of a receiving organism. In the first method, the donor organism is capable of ingesting and digesting omega-3 rich sources, and the receiving organism is incapable of ingesting or digesting omega-3 rich sources. In the second method, the donor organism desires the consumption of omega-3 rich sources, and the receiving organism does not desire the consumption of omega-3 rich sources. In the third method, the donor organism produces omega-3 fatty acids, and the receiving organism is unable to produce omega-3 fatty acids.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Inventor: Sadia Ross Barrameda
  • Publication number: 20150089681
    Abstract: This disclosure provides for compositions and methods for the use of designed nucleic acid-targeting nucleic acids, Argonautes, and complexes thereof.
    Type: Application
    Filed: April 10, 2014
    Publication date: March 26, 2015
    Applicant: Caribou Biosciences, Inc.
    Inventors: John VAN DER OOST, Daniël Christianus SWARTS, Andrew Paul MAY, Rachel E. HAURWITZ
  • Patent number: 8987546
    Abstract: The present invention relates to transgenic fluorescent orange ornamental fish, as well as methods of making such fish by in vitro fertilization techniques. Also disclosed are methods of establishing a population of such transgenic fish and methods of providing them to the ornamental fish industry for the purpose of marketing.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: March 24, 2015
    Assignee: Yorktown Technologies, L.P.
    Inventors: Alan Blake, Richard Crockett, Aidas Nasevicius
  • Publication number: 20150082469
    Abstract: Genetically modified non-human animals comprising a human or humanized interleukin-7 (IL-7) gene. Cells, embryos, and non-human animals comprising a human or humanized IL-7 gene. Rodents that express human or humanized IL-7 protein. Genetically modified mice that comprise a human or humanized IL-7-encoding gene in their germline, wherein the human or humanized IL-7-encoding gene is under control of endogenous mouse IL-7 regulatory sequences.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventor: Andrew J. Murphy
  • Publication number: 20150072064
    Abstract: The present invention relates to methods for transfecting cells. In particular, the present invention relates to methods of transfecting primordial germ cells in avians, and to methods of breeding avians with modified traits.
    Type: Application
    Filed: April 19, 2013
    Publication date: March 12, 2015
    Inventor: Scott Geoffrey Tyack
  • Patent number: 8975467
    Abstract: The present invention relates to transgenic green ornamental fish, as well as methods of making such fish by in vitro fertilization techniques. Also disclosed are methods of establishing a population of such transgenic fish and methods of providing them to the ornamental fish industry for the purpose of marketing.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: March 10, 2015
    Assignee: Yorktown Technologies, L.P.
    Inventors: Alan Blake, Richard Crockett, Aidas Nasevicius
  • Patent number: 8962912
    Abstract: The present invention relates, in general, to development of non-human transgenic animals expressing a human blood clotting factor, such as Factor VIII, Factor VII, Factor IX and von Willebrand factor. The invention further provides methods of detecting immunogenic events against human blood clotting factor using the transgenic animals described.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: February 24, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Maria Sasgary, Maria Schuster, Hans-Peter Schwarz, Birgit Maria Reipert, Gerhard Antoine, Hartmut Ehrlich
  • Patent number: 8921642
    Abstract: Described are transgenic animals for conditional and inducible cell targeting, that express a dimerizable conditional-STOP caspase 3 transgene.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: December 30, 2014
    Assignee: Massachusetts Eye and Ear Infirmary
    Inventors: Albert Edge, Masato Fujioka
  • Patent number: 8878001
    Abstract: Mice that comprise a replacement of endogenous mouse IL-6 and/or IL-6 receptor genes are described, and methods for making and using the mice. Mice comprising a replacement at an endogenous IL-6R? locus of mouse ectodomain-encoding sequence with human ectodomain-encoding sequence is provided. Mice comprising a human IL-6 gene under control of mouse IL-6 regulatory elements is also provided, including mice that have a replacement of mouse IL-6-encoding sequence with human IL-6-encoding sequence at an endogenous mouse IL-6 locus.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: November 4, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Li-Hsien Wang, Anthony T. Dore, Jr., Sean Stevens, Andrew J. Murphy
  • Patent number: 8859280
    Abstract: A composition and method for in vitro fertilization is provided which uses culture media comprising elevated concentrations of lipoic acid. More specifically, the invention provides culture media for developmental cells having a lipoic acid concentration of 5 ?M to 40 ?M. Culture media that include lipoic acid at concentrations within the identified range are able to provide blastocysts with increased survival, increased cell numbers, increased inner cell masses and/or increased percentage of the total mass made up by the inner cell compared to blastocysts cultured in a control medium.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: October 14, 2014
    Assignee: Vitrolife Sweden AB
    Inventors: David K Gardner, Mark G Larman, Donald Linck
  • Patent number: 8785718
    Abstract: Methods of using hypermethylated transposons to create genetically modified animals that express interfering RNAs are described.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: July 22, 2014
    Assignee: Recombinetics, Inc.
    Inventors: Scott C. Fahrenkrug, Daniel F. Carlson, Aron M. Geurts
  • Patent number: 8759105
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: June 24, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aris N. Economides, Andrew J. Murphy, David M. Valenzuela, David Frendewey, George D. Yancopoulos
  • Patent number: 8742085
    Abstract: A method for preparing a transgenic animal of simultaneous multiple-gene expression is provided. Additionally, a method for preparing a transgenic embryo, which introduces both phytase gene and human myxovirus resistant gene A into a target embryo, to obtain a transgenic embryo is provided. The transgenic animal of simultaneous multiple-gene expression can be achieved by transplanting the transgenic embryo into the body of a female target animal. A significant advantage of the foregoing methods, among many others, exists in that the simultaneous expression of multiple genes can be achieved in one transgenosis, which provides a convenient method for the preparation of combined-gene transferred animals.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: June 3, 2014
    Assignee: Institute of Animal Science, Chinese Academy of Agricultural Sciences
    Inventors: Kui Li, Huiming Ju, Junhua Fan, Lijing Bai, Yulian Mu, Shulin Yang, Zhonglin Tang, Wentao Cui
  • Patent number: 8729335
    Abstract: The present invention directs to a transgenic NRIP knockout mouse, the genome of which is manipulated to comprise a disruption of a nuclear receptor interaction protein (NRIP) gene, wherein the NRIP gene is disrupted by deletion of exon 2, the mouse exhibits a phenotype comprising abnormal muscular function. The present invention also directs to a method for making a transgenic NRIP knockout mouse whose genome comprises a homozygous disruption of the NRIP gene, the mouse exhibits abnormal muscular function.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: May 20, 2014
    Assignee: National Taiwan University
    Inventors: Show-Li Chen, Hsin-Hsiung Chen, Kuan-Liang Lin, Wan-Lun Yan
  • Patent number: 8722964
    Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: May 13, 2014
    Assignee: Transposagen Biopharmaceuticals, Inc.
    Inventors: Eric M. Ostertag, John Stuart Crawford
  • Publication number: 20140109244
    Abstract: In one aspect, the invention provides a transgenic non-human animal model havings germ cells and somatic cells containing an endogenous MMTV-SV40-Spy1A gene sequence introduced into said animal model, or an ancestor of said animal model at an embryonic stage, wherein said gene sequence comprises a mouse mammary tumor virus gene (MMTV), a functionally disrupted SV40 gene (SV40) and a human Spy1A gene. In another aspect, the present invention provides a transgenic non-human animal model whose germ cells and somatic cells contain an endogenous Spy1A-pTRE-Tight gene sequence introduced into said animal model or an ancestor of said animal model at an embryonic stage. Preferably, the Spy1A-pTRE-Tight animal model expresses the Spy1A and develop cancer, preferably breast cancer, when administered with tetracycline, preferably doxycycline.
    Type: Application
    Filed: August 30, 2013
    Publication date: April 17, 2014
    Inventors: Lisa Porter, Bre-Anne Fifield, Dorota Lubanska, Espanta Jalili
  • Patent number: 8697940
    Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: April 15, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy
  • Patent number: 8653324
    Abstract: Mice comprising a human p16 transgene operably linked to an inducible promoter and capable of controlled expression of p16 are provided. Also provided are cells, tissues, and organs obtainable from such mice, and methods for producing p16 transgenic mice.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: February 18, 2014
    Assignee: Fox Chase Cancer Center
    Inventor: Greg H. Enders
  • Publication number: 20140041062
    Abstract: The present disclosure relates to an ASD genetically engineered model carrying a deletion of Shank2 gene and having reduced NMDA receptor function. According to the present disclosure, genetically engineered mice that show the clinical features of ASD due to the deletion of the Shank2 gene can be obtained, and the genetically engineered mice can be effectively used to screen candidate therapeutic agents.
    Type: Application
    Filed: August 2, 2013
    Publication date: February 6, 2014
    Applicants: Industry-Academic Cooperation Foundation, Yonsei University, Korea Advanced Institute of Science and Technology, Seoul National University R&DB Foundation
    Inventors: Min Goo Lee, Bong Kiun Kaang, Eunjoon Kim
  • Patent number: 8642835
    Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: February 4, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Sean Stevens, Andrew J. Murphy
  • Publication number: 20130345401
    Abstract: Disclosed is a novel means that enables mass production of highly safe fibrinogen at low cost. The transgenic silkworm of the present invention expresses the fibrinogen subunit A?, B? and ? chains in the silk gland cells and produces fibrinogen having coagulation activity in the cocoon filament. Preferably, the transgenic silkworm expresses the subunits in the middle silk gland cells and produces fibrinogen in the sericin layer of the cocoon filament. By recovering fibrinogen from the cocoon of the transgenic silkworm of the present invention, highly safe fibrinogen can be mass-produced at low cost.
    Type: Application
    Filed: March 2, 2012
    Publication date: December 26, 2013
    Applicant: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD.
    Inventors: Satoshi Sekiguchi, Manabu Takahisa, Masahiro Tomita
  • Patent number: 8581025
    Abstract: The present invention relates to the method and use of reef coral fluorescent proteins in making transgenic red, green and yellow fluorescent zebrafish. Preferably, such fluorescent zebrafish are fertile and used to establish a population of transgenic zebrafish and to provide to the ornamental fish industry for the purpose of marketing. Thus, new varieties of ornamental fish of different fluorescence colors from a novel source are developed.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: November 12, 2013
    Assignee: Yorktown Technologies, L.P.
    Inventors: Alan Blake, Richard Crockett, Jeffrey Essner, Perry Hackett, Aidas Nasevicius
  • Patent number: 8581021
    Abstract: The present invention relates to a genetically modified pig comprising at least one site for integration of at least one transgene. The invention also pertains to a porcine embryo, blastocyst, fetus, donor cell and/or cell nucleus, derived from said genetically modified pig. In another aspect, the invention relates to any genetically modified porcine blastocyst, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: November 12, 2013
    Assignee: Aarhus Universitet
    Inventors: Jacob Giehm Mikkelsen, Brian Moldt, Anders Lade Nielsen, Lars Axel Bolund, Peter Michael Kragh, Jannik Ejnar Jakobsen, Arne Lund Jørgensen
  • Patent number: 8581023
    Abstract: The present invention relates to the method and use of fluorescent proteins in making purple transgenic fluorescent fish. Also disclosed are methods of establishing a population of such transgenic fish and methods of providing them to the ornamental fish industry for the purpose of marketing. Thus, new varieties of ornamental fish of different fluorescence colors from a novel source are developed.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: November 12, 2013
    Assignee: Yorktown Technologies, L.P.
    Inventors: Alan Blake, Richard Crockett, Aidas Nasevicius
  • Patent number: 8581024
    Abstract: The present invention relates to transgenic blue ornamental fish, as well as methods of making such fish by in vitro fertilization techniques. Also disclosed are methods of establishing a population of such transgenic fish and methods of providing them to the ornamental fish industry for the purpose of marketing.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: November 12, 2013
    Assignee: Yorktown Technologies, L.P.
    Inventors: Alan Blake, Richard Crockett, Aidas Nasevicius
  • Patent number: 8558055
    Abstract: The present invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in cytokine-cytokine mediated autoimmune and inflammatory disease. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human autoimmune and inflammatory disease and methods of their use. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a cytokine gene such as the Faslg gene, the Fas gene, etc. In one embodiment, the cytokine gene is the Faslg gene. In another embodiment, the cytokine gene is one of several known cytokine genes, such as Fas, IFN?, TNF-?, IL-2, IL-10, and IL-12.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: October 15, 2013
    Assignee: Transposagen Biopharmaceuticals, Inc.
    Inventors: Eric M. Ostertag, John Stuart Crawford
  • Patent number: 8546644
    Abstract: The invention discloses a recombinant gene which enhances the ability of fish to tolerate low dissolved oxygen (DO) stress and the use thereof. Carp ?-actin gene promoter is used as a promoter and Vitreoscilla hemoglobin gene is used as a target gene, so as to construct the recombinant Vitreoscilla hemoglobin gene driven by carp ?-actin promoter. The modeling organism zebrafish is used as the research object, and the recombinant gene is microinjected into zygotes of zebrafish. After PCR screening and 156 h low DO stress test, transgenic fish are obtained with a survival rate of 92%, which is significantly different from the survival rate of 65% of the control fish group. The vhb transgenic zebrafish obtain hypoxia tolerance. When the recombinant gene is applied to the economically farmed species, i.e., blunt snout bream (Megalobrama amblycephala) and common carp (Cyprinus carpio L.), it enhances their hypoxia tolerance as well.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: October 1, 2013
    Assignees: Institute of Hydrobiology, Chinese Academy of Sciences, Peking University
    Inventors: Wei Hu, Zuoyan Zhu, Hong Ma, Bo Guan, Yuanlei Hu, Zhongping Lin
  • Patent number: 8518392
    Abstract: Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3?-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.
    Type: Grant
    Filed: August 13, 2010
    Date of Patent: August 27, 2013
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David Frendewey, Guochun Gong, Ka-Man Venus Lai, David M. Valenzuela
  • Patent number: 8513485
    Abstract: The invention provides methods for isolating cell-type specific mRNAs by selectively isolating ribosomes or proteins that bind mRNA in a cell type specific manner, and, thereby, the mRNA hound to the ribosomes or proteins that bind mRNA. Ribosomes, which are riboprotein complexes, bind mRNA that is being actively translated in cells. According to the methods of the invention, cells are engineered to express a molecularly tagged ribosomal protein or protein that binds mRNA by introducing into the cell a nucleic acid comprising a nucleotide sequence encoding a ribosomal protein or protein that binds mRNA fused to a nucleotide sequence encoding a peptide tag. The tagged ribosome or mRNA binding protein can then be isolated, along with the mRNA bound to the tagged ribosome or mRNA binding protein, and the mRNA isolated and further used for gene expression analysis.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: August 20, 2013
    Assignee: Envoy Therapeutics, Inc.
    Inventors: Nathaniel Heintz, Tito A. Serafini, Andrew W. Shyjan
  • Patent number: 8487157
    Abstract: Transgenic rodents having NGF beta gene mutants in their genomes express NGF beta mutant proteins. The preparation methods of the transgenic rodents, the methods of utilizing the transgenic animals to prepare NGF beta mutant proteins and the resulting NGF beta mutant proteins are provided. The transgenic rodents are useful in preparing human NGF and in the study of the functions of NGF beta mutants and their receptors in the whole animal level, and also useful for screening and purifying NGF beta mutants which have high activity and high security.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: July 16, 2013
    Assignee: Staidson (Beijing) Pharmaceutical Co., Ltd.
    Inventors: Zhiwen Zhou, Hongshan Zhang, Hongbo Chen
  • Patent number: 8466339
    Abstract: Disruption of mitogen inducible gene 6 (Mig-6) in mice by homologous recombination (KO mice) led to early onset osteoarthritis (OA) as revealed by simultaneous enlargement and deformity of multiple joints, degradation of articular cartilage and the development of bony outgrowths or osteophytes within the joint space. Because of the striking similarity to human OA, Mig-6 KO mice are a useful animal model for studying the mechanism of this disease and for testing new drugs or therapies for treating OA. These KO mice also developed epithelial hyperplasia, adenoma, and adenocarcinoma in organs such as lung, gallbladder, and bile duct. Mig-6 is therefore a tumor suppressor gene and is a candidate gene for the frequent Ip36 genetic alterations found in lung cancer. It can be used as a tumor biomarker as well as a target for cancer therapy.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: June 18, 2013
    Assignee: Van Andel Research Institute
    Inventors: Yu-Wen Zhang, George F. Vande Woude
  • Patent number: 8420886
    Abstract: The invention relates to an animal model of cardiovascular disease and a method of preparation and use thereof. In particular, it relates to a genetically engineered animal model of aortic aneurysms and methods for screening drugs using the animal model. Provided is a genetically-modified, non-human mammal, wherein the modification results in a disrupted Fibulin-4 gene. Also provided is a genetically-modified animal cell containing a disrupted Fibulin-4 gene. The mammal or animal cell can be used as a model for a cardiovascular condition or disease, preferably aortic aneurysm, more preferably thoracic aortic aneurysm. Furthermore, methods for identify or validating a compound that can be used to treat or to prevent an aberrant cardiovascular condition are provided, as well as method to identify a gene involved in the response to aortic failure.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: April 16, 2013
    Assignee: Erasmus University Medical Center Rotterdam
    Inventors: Jeroen Essers, Georgios Aris Garinis, Roland Kanaar
  • Patent number: 8338150
    Abstract: Disclosed is a method for parallel delivery of agents to and/or into a cell structure, wherein at least two electrolyte-filled tubes are provided together with a counter electrode, the tubes being connected to a voltage or current generator, said agents being introduced into the electrolyte solution contained in the tubes, which are placed close to the cell structure, whereupon the agents are transported through the tubes to said cell structure and into the said structure through pores which have been formed by application of an electric field focused on the cell structure, resulting in electroporation of the cell structure. Also different applications of the method is disclosed, e.g. use of the method in order to transfer cell-impermeant solutes, such as drugs or genes, into the cell structure or out of the cell structure.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: December 25, 2012
    Assignee: Cellectricon AB
    Inventors: Owe Orwar, Mattias Karlsson, Kerstein Nolkrantz, Cecilia Farre
  • Patent number: 8309791
    Abstract: Transgenic artiodactyls are described as well as methods of making and using such artiodactyls.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: November 13, 2012
    Assignee: Recombinectics, Inc.
    Inventors: Scott C. Fahrenkrug, Daniel F. Carlson, Aron M. Geurts
  • Patent number: 8278499
    Abstract: Disclosed is a nonhuman animal showing the symptoms of human nonalcoholic steatohepatitis which is obtained by transplanting human hepatocytes into an immunodeficient hepatopathic nonhuman animal to produce a chimeric nonhuman animal and then transplanting human hepatocytes that are propagated in the body of the chimeric nonhuman animal into an immunodeficient hepatopathic nonhuman animal of the same species as the immunodeficient hepatopathic nonhuman animal described above, as well as a nonhuman animal showing the symptoms of human fatty liver which is obtained by transplanting human hepatocytes into an immunodeficient hepatopathic nonhuman animal to produce a chimeric nonhuman animal.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: October 2, 2012
    Assignees: Hiroshima Industrial Promotion Organization, Phoenixbio Co., Ltd., Hiroshima University
    Inventors: Chise Mukaidani, Katsutoshi Yoshizato, Miho Kataoka
  • Patent number: 8268555
    Abstract: Disclosed is a method for sequential delivery of agents to and/or into a cell structure, wherein an electrolyte-filled tube is provided together with a counter electrode, said tube is connected to a voltage or current generator, at least two agents are introduced in a discrete mode into the electrolyte solution contained in the tube, which is placed close to the cell structure, one agent at the time being transported through the tube to and/or into said cell structure in which a pore has been formed by application of an electric field focused on the cell structure, resulting in electroporation of the cell structure. Also different applications of the method is disclosed, e.g. us of the method in order to transfer cell-impermeant solutes, such as drugs or genes, into the cell structure or out of the cell structure.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: September 18, 2012
    Assignee: Cellectricon AB
    Inventors: Owe Orwar, Mattias Karlsson, Cecilia Farre, Kerstin Nolkrantz
  • Publication number: 20120202985
    Abstract: Described herein are recombinant non-human cells and animals having an alteration of the S? region such that there is an elevated IgE level. Also described herein is an alteration in the IgH locus allows for enhanced class switch recombination (CSR) such that the desired heavy chain isotype is expressed at an elevated level relative to an unmodified cell.
    Type: Application
    Filed: February 26, 2010
    Publication date: August 9, 2012
    Applicant: Genentech Inc.
    Inventors: Shahram Misaghi, Ali Zarrin
  • Patent number: 8232451
    Abstract: The present invention relates to transgenic blue ornamental fish, as well as methods of making such fish by in vitro fertilization techniques. Also disclosed are methods of establishing a population of such transgenic fish and methods of providing them to the ornamental fish industry for the purpose of marketing.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: July 31, 2012
    Assignee: Yorktown Technologies, L.P.
    Inventors: Alan Blake, Richard Crockett, Aidas Nasevicius
  • Patent number: 8232450
    Abstract: The present invention relates to the method and use of fluorescent proteins in making purple transgenic fluorescent fish. Also disclosed are methods of establishing a population of such transgenic fish and methods of providing them to the ornamental fish industry for the purpose of marketing. Thus, new varieties of ornamental fish of different fluorescence colors from a novel source are developed.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: July 31, 2012
    Assignee: Yorktown Technologies, L.P.
    Inventors: Alan Blake, Richard Crockett, Aidas Nasevicius
  • Patent number: 8222479
    Abstract: The present invention relates to a recombinant organism having any one of nucleic acids (i) to (iv) introduced therein: (i) a nucleic acid having a base sequence of SEQ ID NO: 1; (ii) a nucleic acid encoding a protein having an amino acid sequence of SEQ ID NO: 2; (iii) a nucleic acid encoding a dragline protein and having a sequence identity of 90% or more with the nucleic acid (i); (iv) a nucleic acid which encodes a dragline protein and hybridizes with a complementary chain of the nucleic acid (i) under stringent conditions.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: July 17, 2012
    Assignee: Okamoto Corporation
    Inventors: Tianfu Zhao, Masao Nakagaki
  • Patent number: 8198507
    Abstract: The invention concerns transgenic or recombinant non-human mammals, wherein the expression of the gene coding for a microtubule associated protein (MAP) is modified (STOP gene) (inactivation or overexpression) and their uses in screening medicines useful in schizophrenia and schizo-affective disorders, with anxious, paranoiac or depressive component.
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: June 12, 2012
    Assignees: Institut National de la Sante Et de la Recherche Medicale - INSERM, Commissariat a l'Energie Atomique Et Aux Energies Alternatives
    Inventors: Annie Andrieux, Didier Job, Eric Denarier, Christophe Bosc, Muriel Vernet
  • Patent number: 8188334
    Abstract: The present invention provides systems that allow reliable multiplexed transformation of Drosophila embryos. The present invention provides methods and reagents that allow preparation of injection-quality nucleic acid samples and that allow simultaneous preparation of multiple such samples. The present invention provides systems for simultaneous processing of multiple injected embryos. The present invention provides methods for transformation of Drosophila embryos involving use of virginator strains that can be used to increase the efficiency of setting up the crosses needed to produce the eggs for the injections and for the crosses needed to screen for transformants.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: May 29, 2012
    Assignee: Genetic Services, Inc.
    Inventors: Susan B. Zusman, Michael Tworoger
  • Patent number: 8173861
    Abstract: The present invention discloses a non-human animal model for a hereditary autosomal dominant disease. The non-human animal model expresses at least one phenotype associated with the disease and is obtained by a genetic determinant. The invention also relates to sperm cells and embryos comprising the genetic determinant for an autosomal dominant disease. Furthermore, methods for producing the non-human animal model, sperm cell, and embryos are disclosed.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: May 8, 2012
    Assignee: Aarhus Universitet
    Inventors: Lone Bruhn Madsen, Christian Bendixen, Knud Larsen, Connie Jakobsen Juhl, Bo Thomsen
  • Patent number: 8173859
    Abstract: An epilepsy model animal (CHRNA4:S284L) developing spontaneous epileptic seizure during sleep, which is a nonhuman animal established by ontogenesis of a totipotent cell into which a polynucleotide encoding nonhuman mutant CHRNA4 is introduced and having said polynucleotide in its somatic chromosome, or a progeny of the nonhuman animal, wherein said nonhuman mutant CHRNA4 has the corresponding mutation of human mutant CHRNA4 in which the 284th Ser of SEQ ID NO: 1 is substituted by Leu. The epilepsy model animal has gene abnormality homologous to human chromosomal dominant nocturnal frontal lobe epilepsy and a symptom (epileptic seizure during sleep) the same as that of human autosomal dominant nocturnal frontal lobe epilepsy.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: May 8, 2012
    Assignee: Japan Science and Technology Agency
    Inventors: Shinichi Hirose, Sunao Kaneko, Motohiro Okada, Ryo Saito
  • Publication number: 20120082987
    Abstract: The present invention relates, in general, to development of non-human transgenic animals expressing a human blood clotting factor, such as Factor VIII, Factor VII, Factor IX and von Willebrand factor. The invention further provides methods of detecting immunogenic events against human blood clotting factor using the transgenic animals described.
    Type: Application
    Filed: March 24, 2011
    Publication date: April 5, 2012
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Maria Sasgary, Maria Schuster, Hans-Peter Schwarz, Birgit Reipert, Gerhard Antoine, Hartmut Ehrlich
  • Patent number: 8148143
    Abstract: A vector and its use to generate genetically modified animals and cells is disclosed. One aspect involves a vector that comprises a sperm cell and one or more polynucleotide molecules bound to a sperm cell through one or more anti-sperm antibody linker. In one preferred embodiment, the one or more polynucleotide molecules encode for a gene product that confers desired characteristics in the cells or the animals. In another preferred embodiment, the genetically modified cells are able to produce desired therapeutic proteins. The association of the sperm, linker, and the one or more polynucleotide can occur in vitro or in vivo. In another embodiment, the genetically modified cells are transgenic chicken eggs in which one or more desired recombinant protein is expressed. In another aspect, genetically modified cells or animals are derived form the fertilization of an animal egg call with the vector described above.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: April 3, 2012
    Assignee: Kwang-Hua Development and Investment Ltd.
    Inventor: Kangsheng Wang
  • Patent number: 8134044
    Abstract: A transgenic animal such as a transgenic snake or other reptile that expresses a heterologous expression product is described, along with methods of making the same. In general, the animal comprises cells containing a sequence encoding the heterologous expression product. The sequence encoding the heterologous expression product is integrated into the genome of the animal (e.g., in some or all cells thereof, and in some embodiments into germ cells thereof). The sequence encoding the heterologous expression product is, in general, operatively associated with an expression sequence or promoter. The animals are useful for, among other things, testing of repellents, testing of toxicological compounds, as teaching aids, for venom production, etc.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: March 13, 2012
    Assignee: North Carolina State University
    Inventors: Paul E. Mozdziak, James N. Petitte
  • Publication number: 20120030783
    Abstract: Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.
    Type: Application
    Filed: September 1, 2011
    Publication date: February 2, 2012
    Applicant: Duke University
    Inventors: James J. Smith, Derek Jantz, Homme W. Hellinga